Safety and Feasibility of Locoregional Platelet-rich Plasma Injection for Iliopsoas Impingement After Total Hip Arthroplasty: A Phase 1 Prospective Observational Study

Overview

Journal Regen Ther

Date 2023 Dec 11

PMID 38077288

Authors

Yasuhiro Homma

Sayuri Uchino

Masashi Nagao

Takanori Wakayama

Shin Fukusato

Tomonori Baba

Taiji Watari

Koju Hayashi

Yoshitomo Saita

Muneaki Ishijima

Affiliations

Soon will be listed here.

Abstract

Introduction: Although numerous studies have reported outcomes with various conservative approaches for the iliopsoas impingement after total hip arthroplasty (THA), reports on the use of locoregional autologous platelet rich plasma (PRP) injections for the iliopsoas impingement after THA are lacking. This phase 1 study therefore aimed to investigate the safety and feasibility of locoregional PRP injection for iliopsoas impingement after THA.

Materials And Methods: Patients diagnosed with iliopsoas impingement after THA who met the criteria for participation (symptoms persisting for more than 3 months, aged 20 years or older, and unable to receive non-steroidal analgesic or anti-inflammatory drugs) were eligible to participate in this clinical study. The primary endpoint was observed adverse events including procedure-related pain, and the secondary endpoints included pain and functionality of the hip joint, that were assessed using the Western Ontario and McMaster Universities Arthritis Index, Japanese Hip Disease Evaluation Questionnaire, and Forgotten Joint Score-12.

Results: Three patients were screened for eligibility, and 3 patients were finally included in this study. Two participants (patients 1 and 2; aged 66 and 65 years, respectively) were female. The third participant (patient 3; age 73 years) was male. All patients experienced adverse events; however, none were found to be serious. None of the patients experienced any infections, or intra- or post-operative symptoms of nerve damage, or subcutaneous haemorrhage owing to the administration of locoregional PRP. Although patient 2 showed almost complete resolution of the symptom, patient 1 and 3 demonstrated persistent groin pain after the injection.

Conclusion: We demonstrated the results of preliminary phase 1 prospective observational clinical study that administration of locoregional PRP injections for iliopsoas impingement following THA is both, safe and feasible.

References

Nishio H, Saita Y, Kobayashi Y, Takaku T, Fukusato S, Uchino S . Platelet-rich plasma promotes recruitment of macrophages in the process of tendon healing. Regen Ther. 2020; 14:262-270. PMC: 7232040. DOI: 10.1016/j.reth.2020.03.009. View

DeLong J, Russell R, Mazzocca A . Platelet-rich plasma: the PAW classification system. Arthroscopy. 2012; 28(7):998-1009. DOI: 10.1016/j.arthro.2012.04.148. View

Kobayashi Y, Saita Y, Takaku T, Yokomizo T, Nishio H, Ikeda H . Platelet-rich plasma (PRP) accelerates murine patellar tendon healing through enhancement of angiogenesis and collagen synthesis. J Exp Orthop. 2020; 7(1):49. PMC: 7343697. DOI: 10.1186/s40634-020-00267-1. View

Mautner K, Colberg R, Malanga G, Borg-Stein J, Harmon K, Dharamsi A . Outcomes after ultrasound-guided platelet-rich plasma injections for chronic tendinopathy: a multicenter, retrospective review. PM R. 2013; 5(3):169-75. DOI: 10.1016/j.pmrj.2012.12.010. View

Momoi Y, Saita Y, Nagao M, Kobayashi Y, Nakajima R, Uchino S . Study protocol for a randomised placebo controlled trial of platelet-rich plasma injection to prevent post-traumatic knee osteoarthritis after anterior cruciate ligament reconstruction. BMJ Open. 2022; 12(11):e061484. PMC: 9685167. DOI: 10.1136/bmjopen-2022-061484. View

Behrend H, Giesinger K, Giesinger J, Kuster M . The "forgotten joint" as the ultimate goal in joint arthroplasty: validation of a new patient-reported outcome measure. J Arthroplasty. 2011; 27(3):430-436.e1. DOI: 10.1016/j.arth.2011.06.035. View

Wakayama T, Saita Y, Kobayashi Y, Nishio H, Uchino S, Fukusato S . Quality comparison between two different types of platelet-rich plasma for knee osteoarthritis. Regen Med Res. 2020; 8:3. PMC: 7721479. DOI: 10.1051/rmr/200002. View

Battaglia M, Guaraldi F, Vannini F, Rossi G, Timoncini A, Buda R . Efficacy of ultrasound-guided intra-articular injections of platelet-rich plasma versus hyaluronic acid for hip osteoarthritis. Orthopedics. 2014; 36(12):e1501-8. DOI: 10.3928/01477447-20131120-13. View

Fader R, Mitchell J, Traub S, Nichols R, Roper M, Mei Dan O . Platelet-rich plasma treatment improves outcomes for chronic proximal hamstring injuries in an athletic population. Muscles Ligaments Tendons J. 2015; 4(4):461-6. PMC: 4327356. View

10.

Araya N, Miyatake K, Tsuji K, Katagiri H, Nakagawa Y, Hoshino T . Intra-articular Injection of Pure Platelet-Rich Plasma Is the Most Effective Treatment for Joint Pain by Modulating Synovial Inflammation and Calcitonin Gene-Related Peptide Expression in a Rat Arthritis Model. Am J Sports Med. 2020; 48(8):2004-2012. DOI: 10.1177/0363546520924011. View

11.

Kraeutler M, Garabekyan T, Mei-Dan O . The use of platelet-rich plasma to augment conservative and surgical treatment of hip and pelvic disorders. Muscles Ligaments Tendons J. 2017; 6(3):410-419. PMC: 5193533. DOI: 10.11138/mltj/2016.6.3.410. View

12.

Uchino S, Saita Y, Wada A, Kobayashi Y, Wakayama T, Nishio H . The immature platelet fraction affects the efficacy of platelet rich plasma therapy for knee osteoarthritis. Regen Ther. 2021; 18:176-181. PMC: 8283129. DOI: 10.1016/j.reth.2021.06.004. View

13.

Matsumoto T, Kaneuji A, Hiejima Y, Sugiyama H, Akiyama H, Atsumi T . Japanese Orthopaedic Association Hip Disease Evaluation Questionnaire (JHEQ): a patient-based evaluation tool for hip-joint disease. The Subcommittee on Hip Disease Evaluation of the Clinical Outcome Committee of the Japanese Orthopaedic Association. J Orthop Sci. 2011; 17(1):25-38. PMC: 3265722. DOI: 10.1007/s00776-011-0166-8. View

14.

Henderson R, Lachiewicz P . Groin pain after replacement of the hip: aetiology, evaluation and treatment. J Bone Joint Surg Br. 2012; 94(2):145-51. DOI: 10.1302/0301-620X.94B2.27736. View

15.

Chalmers B, Sculco P, Sierra R, Trousdale R, Berry D . Iliopsoas Impingement After Primary Total Hip Arthroplasty: Operative and Nonoperative Treatment Outcomes. J Bone Joint Surg Am. 2017; 99(7):557-564. DOI: 10.2106/JBJS.16.00244. View

16.

Nunley R, Wilson J, Gilula L, Clohisy J, Barrack R, Maloney W . Iliopsoas bursa injections can be beneficial for pain after total hip arthroplasty. Clin Orthop Relat Res. 2009; 468(2):519-26. PMC: 2807015. DOI: 10.1007/s11999-009-1141-y. View

17.

Saita Y, Kobayashi Y, Nishio H, Wakayama T, Fukusato S, Uchino S . Predictors of Effectiveness of Platelet-Rich Plasma Therapy for Knee Osteoarthritis: A Retrospective Cohort Study. J Clin Med. 2021; 10(19). PMC: 8509123. DOI: 10.3390/jcm10194514. View

18.

Mlynarek R, Kuhn A, Bedi A . Platelet-Rich Plasma (PRP) in Orthopedic Sports Medicine. Am J Orthop (Belle Mead NJ). 2016; 45(5):290-326. View

19.

Fang J, Wang X, Jiang W, Zhu Y, Hu Y, Zhao Y . Platelet-Rich Plasma Therapy in the Treatment of Diseases Associated with Orthopedic Injuries. Tissue Eng Part B Rev. 2020; 26(6):571-585. PMC: 9208862. DOI: 10.1089/ten.TEB.2019.0292. View

20.

Kobayashi Y, Saita Y, Nishio H, Ikeda H, Takazawa Y, Nagao M . Leukocyte concentration and composition in platelet-rich plasma (PRP) influences the growth factor and protease concentrations. J Orthop Sci. 2016; 21(5):683-9. DOI: 10.1016/j.jos.2016.07.009. View